Clinical Trial Design for FemTech Medical Devices

For FemTech medical devices, Designing clinical trials means navigating distinct obstacles (spanning historically excluded female populations, hormonally variable endpoints, and underfunded therapeutic fields), and knowing these factors separates a trial that produces credible evidence from one stalling at regulatory approval. Fix those issues and the remaining regulatory work turns procedural, not existential.

FemTech medical devices' clinical validation problem versus wellness apps

It includes fertility, menstruation, menopause, pregnancy, contraception, and health across pelvic wellness and sexual health, via apps, wearables, diagnostics, and standalone medical devices.

The funding matches that ambition. Research and Markets values the field in 2025 at $46.47 billion, rising by 2030 to $118.99 billion at a compound rate of 20.8%, while North America has 54.40% of the market that year. That's pharmaceutical-sector scale, nothing like app-store scale.

Still, plenty of FemTech tools covering sexual health, hormonal monitoring, or fertility launch without any peer-reviewed backing or regulatory clearance. That difference counts because these tools now say they can predict ovulation, flag a lost pregnancy, or guide contraception while staying in a regulatory gray area more like step-tracking software than a diagnostic. A wellness tool that gets your step count wrong is an annoyance. When your fertile window gets misreads by a fertility app, the failure matters more, as the industry's trajectory has reached a scale where clinicians, regulators, and investors see that gap as central.

The historical exclusion of women from clinical research still shapes trial design today

By 2025, males make up roughly 75% of those enrolled in clinical trial research, versus about 25% females, and under one fifth of all reproducible health data looks at women's physiology. That gap is substantial, and it leaves countless "standard" trial protocols, built on a male physiological baseline, unable to adapt to female bodies without real redesign work. That's why most "standard" trial protocols, built around a male physiological baseline, won't translate cleanly to female bodies without genuine redesign work.

Funding shows the same pattern. Silicon Valley Bank pointed out that historically only 4% of biopharma R spending covered conditions specific to females, while it tracked a $2.6 billion surge in funding for women's health during 2024 meant as a reversal of that decades-long pattern.

Some gains have lasted. The NIH's Sex as a Biological Variable rule raised design standards domestically, but adoption in global research landscapes stays inconsistent. Frontiers in Global Women's Health lays out the fuller issue in a 2026 paper: systemic, regulatory, data-related, access-related, and other barriers all build on one another. More funding by itself couldn't solve it.

Clinical trial locations in FemTech and untested categories

FemTech trial work leans heavily to one side. Fertility, pregnancy dominate, but sexual health, with clear consumer interest, makes up only 3.4% of the trials. There is obvious consumer demand in that area. Evidently, researchers are not creating the evidence base for them.

Fertility products show an odd pattern. Its patent-to-trial figure of 4.21 tops every FemTech category, meaning companies are filing patents faster than they generate clinical evidence. Maybe firms are choosing direct-to-consumer revenue over the slower work of proving their devices clinically, or maybe real regulatory friction is blocking fertility trials. Both readings point to the same gap.

Pregnancy tools seem healthier in contrast: its 0.25 patents ratio points to research and commercialization advancing in step, not one outpacing its peer. By 2030, over one billion people will enter perimenopause or the menopause transition, yet the clinical evidence base still trails their numbers and rising need.

FDA classification of FemTech devices and the evidence standard each classification triggers

The FDA puts medical devices into tiers, and a FemTech tool's tier determines the amount of clinical evidence required before it can be sold. Class I devices count as low-risk and follow basic controls. Class II devices are moderate-risk and clear via 510(k) or De Novo.

Most devices sit in between. About 90% of devices in FDA premarket go into moderate-risk, while under 10% of 510(k) clearances rely on premarket clinical evidence. Here's an underappreciated takeaway for FemTech founders, a team aiming at 510(k) clearance can usually skip a clinical trial entirely, yet it must still defend why nonclinical evidence, meaning bench testing, biocompatibility data, and predicate device comparison, stands alone.

PMA is its own thing. Sponsors need evidence that offers reasonable assurance the device's specific purpose won't hurt anyone, and this pathway is where most implantable Class III devices for reproductive health end up. Novo, meanwhile, is for truly new devices without a predicate, as with afirst-in-class hormone-tracking wearable that makes clinical assertions.

EU MDR requirements and the parallel evidence burden for European market entry

Without CE marking, no business can enter or grow inside the European market under EU MDR 2017/745, a rule that explicitly applies to software a maker intends for medical purposes spanning diagnosis, prevention, monitoring, prediction, prognosis, therapy, or symptom care. For FemTech, that software point matters enormously, since so many are apps and algorithms, not physical devices.

MDR demands a lot more than the MDD, its predecessor. Clinical evidence standards increased; mandatory post-market clinical follow-up followed, with Notified Body oversight covering more device groups than earlier.

EUDAMED enrollment is compulsory for MDR and IVDR devices hitting the market May 28, 2026, and legacy devices have until November 27, 2026 to comply. The European Commission proposed a plan to simplify MDR in December 2025, and Rule 11, the rule for software classification, could reshuffle where AI-powered FemTech apps land.

Endpoint selection for hormonally variable populations: the core methodological challenge

Hormonal variability makes up the actual physiological environment in which the device must work. That actual physiological environment is where the device must work; endpoints that skip it generate data that breaks down once real people try it.

Consider cycle phase. Baseline readings vary for temperature, glucose, cortisol, and heart rate variability, all biomarkers FemTech wearables record routinely. A trial that omits cycle phase from its measurement protocol up front ends up with data that no one can interpret, not merely data that's messy. This is a failure of design, not statistics, and it explains why otherwise well-run trials often produce data that can't be used.

Menopause brings another wrinkle. During perimenopause, cycles turn irregular and hormone readings shift unpredictably. The "stable baseline" assumption baked into most standard trial protocols simply doesn't hold for this population.

Pregnancy is a separate physiological phase, and a 2024 study with the Oura Ring tracked 120 pregnancies, showing that continuous tracking of body temperature, heart rate, and heart-rate variability could reveal patterns linked to pregnancy loss, specifically pregnancies ending within the initial trimester. This insight generalizes beyond that single paper: you need to stratify by trimester as a variable.

Recruitment strategies for populations that have historically avoided or been excluded from trials

It makes sense that female patients, especially patients of color, distrust clinical research, given a system that under-included these populations and outright harmed them at times over decades. That reaction makes sense: for years, the research system has under-included these populations and, at times, outright harmed them. Recruitment must reckon with that past instead of expecting a standard enrollment funnel to fill on its own.

Community-based outreach and advocacy partnerships regularly beat clinic-based recruitment in FemTech trials. Reproductive health groups and menopause networks aren’t places to buy ads, they’re relationships built on credibility, and that difference should shape how a sponsor shows up from the start.

Decentralized trial methods remove specific barriers that disproportionately leave female patients out: childcare, work schedules that are inflexible, academic medical centers being too far away, and reproductive or in-person pelvic exams that understandably cause discomfort. Natural Cycles was the initial contraception software cleared by the FDA, which serves as a strong example. It processes over 20 million temperature readings daily and posts a 98% effectiveness rate when followed correctly, and engagement at that scale proves how much a tool can achieve once it earns the confidence for sustaining real longitudinal data from its base of female users.

Funding constraints specific to FemTech trials and strategies that have gained traction

FemTech funding tells a pretty clear story. Historically, biopharma R&D put only 4% toward conditions specific to women, and founder-side figures are no less lopsided: in 2025, all-female founding groups received merely 0.6% in VC funding, even though women represented 85% among FemTech founders. Female investors occupy just 17% of VC decision-making seats, a composition gap that's far from incidental because it shapes the clinical evidence standards they feel confident backing.

The squeeze is plain in the launch data: 53 FemTech companies formed in 2024, a slide from 163 in 2023 and 508 in 2020. Fewer companies even reach clinical stages, so trial design has to work from the start, because they can’t absorb a failed study or an underpowered one.

Several strategies have taken hold in this situation. Adaptive trial designs let sponsors run interim analyses and re-estimate sample size partway through, so a failing trial can be abandoned or redirected at less expense. Platform trials let different device studies run on a single setup, so sponsors pay for the infrastructure once instead of many times. Real-world evidence more often works as a complement alongside prospective trials, or sometimes partly stands in for them, when FDA guidance says it can. Teaming up with academic medical centers and women's health research institutes gives a startup the in-kind support, patient pools, and credibility needed to unlock NIH and foundation grants it would miss otherwise. Strategic NIH backing through SBIR and STTR, BARDA, and women's health-focused philanthropy now brings in real money precisely because venture capital hasn't shown up.

FDA's December 2025 real-world evidence guidance and new options for FemTech submissions

On December 18, 2025, FDA released guidance clarifying how it evaluates real-world data when deciding whether real-world evidence can support regulatory medical device decisions, superseding the agency's 2017 guidance. FemTech hasn't seen a consequential regulatory shift this big in ages, since the sector's strength comes from the same longitudinal consumer data covered by this guidance.

Sponsors can now submit real-world evidence for some device applications without providing individually identifiable data. This update strips a data-sharing hurdle that proved a real obstacle to FemTech companies holding huge consumer health datasets they felt reluctant, or unable, to release in identifiable shape.

Under the FDA, real-world data explicitly covers health and medical sources, plus data gathered from digital tools, registries, and more. Wearable and software data meet that definition without stretching. Millions of logged cycles from a wearable tracking fertility, or longitudinal symptom data gathered over many months by a menopause tool, can plausibly back up a regulatory filing in ways that weren't possible earlier.